We have previously found, in rat striatal membrane preparations, that stimulation of adenosine A2 receptors (with the selective adenosine A2 receptor agonist CGS 21680) increases the high- and low-affinity dissociation constants and increases the proportion of high-affinity dopamine D2 receptor binding sites labelled with the selective dopamine D2 receptor antagonist [3H]raclopride. As guanine nucleotides and divalent cations (such as Mg2+) are known to regulate the proportion of high-affinity D2 receptor binding sites in opposing ways, interaction experiments with CGS 21680, the GTP analogue Gpp(NH)p and MgCl2 were performed. Our results suggest that these three factors exert significant, though independent, effects on the proportion of high affinity D2 receptors, and that A2 receptors regulate both the affinity of D2 receptors and the transduction of the signal from the D2 receptor to the G-protein.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0922-4106(93)90157-5DOI Listing

Publication Analysis

Top Keywords

adenosine receptor
8
receptor agonist
8
gtp analogue
8
cgs 21680
8
proportion high-affinity
8
dopamine receptor
8
receptor binding
8
binding sites
8
affinity receptors
8
receptor
6

Similar Publications

The A Adenosine Receptor (AAR) is an important therapeutic target due to its role in inflammation and immune response regulation. Herein, we synthesized and evaluated 5'-deoxy-adenosine derivatives with oxygen at the 4'-position, comparing them to previously studied 4'-thionucleosides. Compound exhibited the highest binding affinity ( = 5.

View Article and Find Full Text PDF

Effects of tryptophan-selective lipidated GLP-1 peptides on the GLP-1 receptor.

J Endocrinol

January 2025

N Inagaki, Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs such as liraglutide and semaglutide are acylated with fatty acids to delay their degradation by dipeptidylpeptidase-4 (DPP-4), the manufacturing process is challenging. We previously developed selectively lipidated GLP-1 peptides at their only tryptophan residue (peptide A having one 8-amino-3,6-dioxaoctanoic acid (miniPEG) linker and peptide B having three miniPEG linkers).

View Article and Find Full Text PDF

The expression of CD38 by cancer cells may mediate an immune-suppressive effect by producing Extracellular Adenosine (ADO) acting through G-protein-coupled cell surface receptors on cellular components and tumor cells. This can increase PD-1 expression and interaction with PD-L1, suppressing CD8 + cytotoxic T cells. This study examines the impact of heightened CD38 expression and extracellular ADO on various hematological and clinical parameters in patients with mature B-cell lymphoma, alongside their correlation with the soluble counterparts of the PD-1/PD-L1 axis.

View Article and Find Full Text PDF

[Berberine regulates glucose and lipid metabolism via clock-controlled genes to ameliorate insulin resistance of hepatocytes].

Zhongguo Zhong Yao Za Zhi

December 2024

Jiangxi Province Key Laboratory of Traditional Chinese Medicine Etiopathogenisis & Research Center for Differentiation and Development of Traditional Chinese Medicine Basic Theory, Jiangxi University of Chinese Medicine Nanchang 330004,China.

This study aims to investigate the mechanism of berberine in regulating the metabolism network via clock-controlled genes represented by brain and muscle arnt-like 1(BMAL1) to ameliorate insulin resistance(IR) of hepatocytes in vitro. The HepG2 cell model of dexamethasone-induced IR(IR-HepG2) was established and treated with 5, 10, and 20 μmol·L~(-1) berberine, respectively, for 24 h. The glucose oxidase method and cell counting kit-8(CCK-8) assay were employed to measure extracellular glucose concentration and cell viability, respectively.

View Article and Find Full Text PDF

Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.

Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!